|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brown T, Pilkington G, Bagust A, Boland A,
Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C,
Greenhalgh J, et al: Clinical effectiveness and cost-effectiveness
of first-line chemotherapy for adult patients with locally advanced
or metastatic non-small cell lung cancer: A systematic review and
economic evaluation. Health Technol Assess. 17:1–278. 2013.
|
|
3
|
Macedo-Pérez EO, Morales-Oyarvide V,
Mendoza-García VO, Dorantes-Gallareta Y, Flores-Estrada D and
Arrieta O: Long progression-free survival with first-line
paclitaxel plus platinum is associated with improved response and
progression-free survival with second-line docetaxel in advanced
non-small-cell lung cancer. Cancer Chemother Pharmacol. 74:681–690.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang X, Ling MT, Guan XY, Tsao SW, Cheung
HW, Lee DT and Wong YC: Identification of a novel function of
TWIST, a bHLH protein, in the development of acquired taxol
resistance in human cancer cells. Oncogene. 23:474–482. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao W, Zhou Y, Xu H, Cheng Y and Kong B:
Snail family proteins in cervical squamous carcinoma: Expression
and significance. Clin Invest Med. 36:E223–E233. 2013.PubMed/NCBI
|
|
9
|
Bowen KA, Doan HQ, Zhou BP, Wang Q, Zhou
Y, Rychahou PG and Evers BM: PTEN loss induces epithelial -
mesenchymal transition in human colon cancer cells. Anticancer Res.
29:4439–4449. 2009.PubMed/NCBI
|
|
10
|
Soria JC, Lee HY, Lee JI, Wang L, Issa JP,
Kemp BL, Liu DD, Kurie JM, Mao L and Khuri FR: Lack of PTEN
expression in non-small cell lung cancer could be related to
promoter methylation. Clin Cancer Res. 8:1178–1184. 2002.PubMed/NCBI
|
|
11
|
Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS,
Lee EB, Cha SI, Yoon GS, Kim CH and Jung TH: PTEN mutations and
relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small
cell lung cancers. Lung Cancer. 69:279–283. 2010. View Article : Google Scholar
|
|
12
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moustakas A and Heldin CH: Signaling
networks guiding epithelial-mesenchymal transitions during
embryogenesis and cancer progression. Cancer Sci. 98:1512–1520.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang J, Zhang Y, Yu C, Li Z, Pan Y and
Sun C: MicroRNA-492 expression promotes the progression of hepatic
cancer by targeting PTEN. Cancer Cell Int. 14:952014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F,
Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z and Chun-Sheng
K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell
proliferation and radioresistance by targeting PTEN. BMC Cancer.
10:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gibbons DL, Lin W, Creighton CJ, Rizvi ZH,
Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y,
Pertsemlidis A, et al: Contextual extracellular cues promote tumor
cell EMT and metastasis by regulating miR-200 family expression.
Genes Dev. 23:2140–2151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang P, Liu H, Xia F, Zhang QW, Zhang YY,
Zhao Q, Chao ZH, Jiang ZW and Jiang CC: Epithelial-mesenchymal
transition is necessary for acquired resistance to cisplatin and
increases the metastatic potential of nasopharyngeal carcinoma
cells. Int J Mol Med. 33:151–159. 2014.
|
|
19
|
Reka AK, Chen G, Jones RC, Amunugama R,
Kim S, Karnovsky A, Standiford TJ, Beer DG, Omenn GS and Keshamouni
VG: Epithelial-mesenchymal transition-associated secretory
phenotype predicts survival in lung cancer patients.
Carcinogenesis. 35:1292–1300. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee MS, Kim HP, Kim TY and Lee JW:
Gefitinib resistance of cancer cells correlated with
TM4SF5-mediated epithelial-mesenchymal transition. Biochim Biophys
Acta. 1823:514–523. 2012. View Article : Google Scholar
|
|
21
|
Jiao M and Nan KJ: Activation of PI3
kinase/Akt/HIF-1α pathway contributes to hypoxia-induced
epithelial-mesenchymal transition and chemoresistance in
hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.
|
|
22
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Frankel LB, Christoffersen NR, Jacobsen A,
Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is
an important functional target of the microRNA miR-21 in breast
cancer cells. J Biol Chem. 283:1026–1033. 2008. View Article : Google Scholar
|
|
25
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dews M, Homayouni A, Yu D, Murphy D,
Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, et
al: Augmentation of tumor angiogenesis by a Myc-activated microRNA
cluster. Nat Genet. 38:1060–1065. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang K: Biotech comes to its ‘antisenses’
after hard-won drug approval. Nat Med. 19:2522013. View Article : Google Scholar
|
|
28
|
Bockhorn J, Dalton R, Nwachukwu C, Huang
S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, et al:
MicroRNA-30c inhibits human breast tumour chemotherapy resistance
by regulating TWF1 and IL-11. Nat Commun. 4:13932013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren J, Chen Y, Song H, Chen L and Wang R:
Inhibition of ZEB1 reverses EMT and chemoresistance in
docetaxel-resistant human lung adenocarcinoma cell line. J Cell
Biochem. 114:1395–1403. 2013. View Article : Google Scholar
|
|
30
|
Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu
Z, Li X and Wu M: MiR-429 inhibits cells growth and invasion and
regulates EMT-related marker genes by targeting Onecut2 in
colorectal carcinoma. Mol Cell Biochem. 390:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JY, Park MK, Park JH, Lee HJ, Shin DH,
Kang Y, Lee CH and Kong G: Loss of the polycomb protein Mel-18
enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2
expression through the downregulation of miR-205 in breast cancer.
Oncogene. 33:1325–1335. 2014. View Article : Google Scholar
|
|
32
|
Alimonti A, Carracedo A, Clohessy JG,
Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ,
Brogi E, et al: Subtle variations in Pten dose determine cancer
susceptibility. Nat Genet. 42:454–458. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aguissa-Touré AH and Li G: Genetic
alterations of PTEN in human melanoma. Cell Mol Life Sci.
69:1475–1491. 2012. View Article : Google Scholar
|
|
34
|
Liu ZL, Wang H, Liu J and Wang ZX:
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and
chemo- or radioresistance in non-small cell lung cancer cells by
targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar
|
|
35
|
Wu Z, He B, He J and Mao X: Upregulation
of miR-153 promotes cell proliferation via downregulation of the
PTEN tumor suppressor gene in human prostate cancer. Prostate.
73:596–604. 2013. View Article : Google Scholar
|
|
36
|
Yang TS, Yang XH, Wang XD, Wang YL, Zhou B
and Song ZS: MiR-214 regulate gastric cancer cell proliferation,
migration and invasion by targeting PTEN. Cancer Cell Int.
13:682013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Q, Li SH, Wang H, Xiao Y, Sahin O,
Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, et al: Concomitant
targeting of tumor cells and induction of T-cell response
synergizes to effectively inhibit trastuzumab-resistant breast
cancer. Cancer Res. 72:4417–4428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schwind S, Maharry K, Radmacher MD, Mrózek
K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler
KH, et al: Prognostic significance of expression of a single
microRNA, miR-181a, in cytogenetically normal acute myeloid
leukemia: A Cancer and Leukemia Group B study. J Clin Oncol.
28:5257–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
